During antibiotic therapy for pneumonia, a female patient develops a vaginal yeast infection. What caused this?

Choice A reason: Carbapenems, like imipenem, are broad-spectrum antibiotics reserved for severe, multidrug-resistant infections. They are not first-line for uncomplicated urinary tract infections due to their potency and risk of promoting resistance. Sulfonamides are more commonly used for UTIs due to their efficacy and specificity.

Choice B reason: Sulfonamides, like trimethoprim-sulfamethoxazole, are especially useful for urinary tract infections. They inhibit bacterial folate synthesis, targeting pathogens like Escherichia coli, a common UTI cause. Their concentration in urine enhances efficacy, making them a first-line choice for uncomplicated UTIs in susceptible organisms.

Choice C reason: Tetracyclines, like doxycycline, are not typically used for urinary tract infections. They are effective for other infections, like chlamydia, but their spectrum and renal clearance make them less ideal for common UTI pathogens like E. coli compared to sulfonamides or nitrofurantoin.

Choice D reason: Macrolides, like erythromycin, are used for respiratory or soft tissue infections, not primarily for urinary tract infections. They have limited activity against common UTI pathogens like E. coli and do not concentrate effectively in urine, making sulfonamides a more appropriate choice.

Choice A reason: Fluticasone, an inhaled corticosteroid, reduces airway inflammation for long-term asthma control. Its onset is too slow (hours to days) for acute asthma attacks, which require rapid bronchodilation. It is used for maintenance, not rescue, as it does not provide immediate relief of bronchospasm.

Choice B reason: Ipratropium, an anticholinergic, is used in COPD or as an adjunct in severe asthma. It blocks muscarinic receptors, reducing bronchoconstriction, but its onset (15-30 minutes) is slower than albuterol’s. It is not the first-line choice for acute asthma, where rapid-acting beta-agonists are preferred.

Choice C reason: Albuterol, a short-acting beta-2 agonist, is the first-line treatment for acute asthma attacks. It rapidly binds beta-2 receptors, increasing cyclic AMP to relax airway smooth muscle, relieving bronchospasm within minutes. Its quick onset makes it ideal for rescue therapy in acute asthma exacerbations.

Choice D reason: Salmeterol, a long-acting beta-2 agonist, provides sustained bronchodilation (up to 12 hours) for asthma maintenance. Its slow onset (20-30 minutes) makes it unsuitable for acute asthma attacks, where immediate relief is critical. It is used to prevent, not treat, acute symptoms.